drugset / Trial / NCT00914212

A Functional Magnetic Resonance Imaging (fMRI) Study in Overweight and Obese Men (0000-103)

NCT00914212

Phase 1 Completed 15 enrolled Merck Sharp & Dohme LLC
RandomizedCrossoverDouble-blindDiagnostic

Summary

This study will determine whether BOLD-fMRI can be used to probe hunger and satiety states in healthy overweight or obese men and also whether fasted/fed fMRI signals can be modulated by sibutramine.

Timeline

Start
2009-05
Primary completion
2009-08
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sibutramine Small molecule 30 mg

Indications